Context: An increase of bile acids (BAs), fibroblast growth factor 19 (FGF19), and glucagon-like peptide 1 (GLP-1) has been implicated in metabolic improvements after Roux-en-Y gastric bypass and vertical sleeve gastrectomy. However, data are still conflicting regarding their role after laparoscopic adjustable gastric banding (LAGB).
O verweight and obesity have evolved into a global pandemic, reaching a worldwide prevalence of 40% (1) . It is well known that adiposity is associated with a state of chronic low-grade inflammation (2) , resulting in various facets of the metabolic syndrome, including cardiovascular disease, type 2 diabetes mellitus (3), nonalcoholic fatty liver disease, and steatohepatitis (4) .
Weight loss attenuates low-grade inflammation and is highly effective in reducing obesity-related diseases (5) . In clinical practice, conventional therapy, combining behavioral and medical interventions, has only had limited success (6) . Bariatric procedures as an alternative strategy to induce weight loss have shown a more sustainable weight reduction as well as amelioration of metabolic parameters with follow-up periods of #15 years (7, 8) . This has been accompanied by a substantial reduction of objective endpoints, such as cardiovascular events and overall mortality (9) at, however, the expense of severe, potentially lethal complications. Therefore, the indication criteria for bariatric procedures are strict (10) .
The initial assumption that weight loss and metabolic improvements result from calorie restriction (4) has recently been challenged (11) . This was driven by clinical observations in which reductions in fasting glucose levels were detected in patients after bariatric surgery even before weight loss started, implying that mechanisms other than weight loss might be relevant (12) .
Numerous clinical studies have reported a substantial increase of bile acids (BAs) and BA-induced hormones after bariatric surgery (13) (14) (15) (16) . Most interestingly, both human and animal studies have identified an intimate interrelation between metabolic improvements, the induction of incretin hormones, and concentrations of circulating BAs after bariatric surgery (13) . BA sequestrants have also been shown to improve glucose metabolism in diabetic patients, most likely via changes in the BA pool composition and induction of incretin hormones (17) . Therefore, data indicate that BAs are important and, thus far, underappreciated regulators of energy and glucose metabolism (11) . Via binding to the ligand-activated transcription factor farnesoid X receptor (FXR) within hepatocytes, BAs can directly downregulate genes involved in gluconeogenesis and promote glycogen synthesis, resulting in decreased blood glucose levels (18) . FXR is also highly expressed in villous enterocytes in the ileum (19) , where BAs induce fibroblast growth factor 19 (FGF19), which enters the liver via the portal circulation. By binding to its receptor complex fibroblast growth factor receptor 4/b-Klotho, FGF19 suppresses BA synthesis and activates hepatic protein and glycogen synthesis (20) .
Furthermore, BAs modulate glucose metabolism, both directly via the Takeda G-protein-coupled receptor 5 (TGR5) on pancreatic b-cells (21) and indirectly via GLP-1 release through TGR5 on enteroendocrine L-cells (22) .
Current data are ambiguous about alterations in BA levels according to the surgical procedure. Numerous studies have not only indicated more pronounced metabolic improvement after Roux-en-Y gastric bypass (RYGB) compared with laparoscopic adjustable gastric banding (LAGB), but have also reported that BAs, GLP-1, and FGF19 are solely elevated in patients undergoing RYGB (15, 23) . It has been claimed that the altered anatomy, enhancing BA reabsorption and delivery of BAs to the L-cells, explains the observed differences between RYGB and LAGB (23, 24) . However, elevated BA levels have also been observed after vertical sleeve gastrectomy in which the anatomic alterations are less pronounced (13) . Furthermore, it is still debated whether changes in BA levels correlate with GLP-1 and FGF19 expression (13, 15, 16, 24) .
In consideration of the conflicting results, further investigations to clarify the role of BAs after bariatric surgery are needed. We analyzed the effects of LAGB on BA levels and FGF19 and GLP-1 concentrations in a cohort of 20 patients. Longitudinal assessment of metabolic and inflammatory parameters before and 3, 6, and 12 months after surgery allowed for detailed analysis of the correlations between the changes in the BA profile and immunometabolic processes. Furthermore, liver specimens were obtained before and 6 months after LAGB to analyze the expression and regulation of FXR and FXRassociated pathways.
Materials and Methods

Study subjects
A total of 20 obese patients (7 men and 13 women) with a body mass index (BMI) .40 kg/m 2 or a BMI .35 kg/m 2 and $1 comorbidity scheduled to undergo LAGB were enrolled in the present study. Some of these patients had already been the subject of previous reports (5, 25, 26) . The selection and preoperative assessment of patients considered for placement of an adjustable gastric band device were performed in our outpatient clinic for metabolic diseases. All patients had a minimum 5-year history of unsuccessful attempts of dietary weight reduction. Type 2 diabetes mellitus, defined as fasting plasma glucose $126 mg/dL, was diagnosed in 1 patient and impaired fasting glucose (fasting plasma glucose, 100 to 125 mg/dL) in 5 of the 20 patients before LAGB. None of the diabetic subjects received any medical treatment. Patients with chronic liver diseases, including autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, hemochromatosis, Wilson's disease, and a1-antitrypsin deficiency, were excluded. Screening test results for all patients were negative for hepatitis B and C. None of the subjects had a current or past alcohol intake of .20 g/wk. Eligible patients underwent LAGB at the Department of Surgery (Medical University Innsbruck). All patients provided written informed consent. The study was performed in accordance with the ethical guidelines of the Declaration of Helsinki, and the local ethical studies committee of Medical University Innsbruck, Austria, approved the present study.
Anthropometry and clinical functional variables
A complete physical examination was performed on each study participant before and 6 and 12 months after bariatric surgery, including the assessment of body height and weight, with calculation of the BMI.
Specimen sampling
Venous blood was drawn after an overnight fast into Sarstedt monovettes at the LAGB procedure and 3, 6, and 12 months after surgery. To retrieve plasma, blood was collected in tubes containing EDTA and then centrifuged at 2000 RCF for 15 minutes at 4°C and stored at 280°C until further use. An extensive panel of routine biochemical parameters was assayed at our central laboratory of the Tirol Kliniken (University Hospital Innsbruck) under controlled and International Organization for Standardization-certified conditions. Specific parameters such as GLP-1, FGF19 and leptin were analyzed using enzyme-linked immunosorbent assays [GLP-1, inactive forms GLP-1 (9-36) and GLP-1 (9-37) amide, measurement range, 1.25 to 80.00 pmol/L; Immuno-Biological Laboratories Co., Ltd., Gunma, Japan; Human FGF19 Quantikine ELISA (enzyme-linked immunosorbent assay) Kit; R&D Systems, Minneapolis, MN; Human Leptin Quantikine ELISA Kit, R&D Systems). Insulin resistance was calculated using the homeostasis model assessment (HOMA) index as follows: HOMA index = fasting insulin (mU/L) 3 plasma glucose (mg/dL)/405. In addition, an index liver biopsy was obtained under laparoscopic guidance during LAGB surgery, and a follow-up liver biopsy was obtained using ultrasound guidance 6 months after LAGB. One sample was placed in 10% buffered formalin for the histologic evaluation, another sample was snap-frozen and stored at 280°C for subsequent messenger RNA (mRNA) extraction.
Immunohistochemistry
Sections, 3 to 4 mm, were prepared from formalin-fixed, paraffin-embedded specimens from the liver biopsy samples. The sections were then deparaffinized in xylene and rehydrated in graded alcohol. Antigens were retrieved using a heat-induced antigen retrieval technique. Endogenous peroxidase activity was quenched with 3% hydrogen peroxide, and nonspecific protein binding sites were blocked using 2.5% bovine serum albumin. A rabbit polyclonal antibody targeting FXR (NR1H4) from LifeSpan BioSciences, Inc. (Seattle, WA), was applied. FXR was visualized using an ImmPRESS horseradish peroxidase-conjugated polymeric system from Vector Laboratories (Burlingame, CA), together with 3-amino-9-ethylcarbazole as a chromogen. For control slides, the first antibody was omitted or blocked by specific immunization peptides. The slides were counterstained with hematoxylin and mounted aqueously. All slides were scanned and digitalized using a Pannoramic SCAN (3DHistech, Budapest, Hungary) equipped with a Zeiss Plan-Apochromat 203/0.8 objective (Carl Zeiss Microscopy, Oberkochen, Germany) and analyzed using Pannoramic Viewer, version 1.15, analysis software. Immunopositivity was quantified using Adobe Photoshop (San Jose, CA).
RNA extraction, microarrays, and quantitative real-time polymerase chain reaction
The steady-state tissue mRNA level of FXR was assessed using semiquantitative real-time polymerase chain reaction (PCR), as described previously (26) . In brief, liver tissue was homogenized in TRIzol reagent (Invitrogen, Thermo Fisher Scientific Life Sciences, Waltham, MA), according to the manufacturer's instructions to extract total RNA. Subsequently, 1 mg of RNA was reverse transcribed using random hexamers (Roche, Basel, Switzerland) and Moloney murine leukemia virus reverse transcription (Invitrogen). Complementary DNAs were then used for PCR analysis with a SYBR Green Master Mix (Eurogentec, Seraing, Belgium). Measurements were performed using a Stratagene Mx3000P bioanalyzer (Stratagene, Amsterdam, The Netherlands). Expression levels were calculated using the standard-curve method. Complementary DNA of HepG2 served as the standard for all measurements. The abundance of mRNA was expressed as a ratio to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA expression. The following primers were used: GAPDH forward:
For microarray analysis, total RNA from liver specimens was extracted as described and analyzed using the human transcriptome array, version 2.0 (Affymetrix, Thermo Fisher Scientific Life Sciences). Detailed descriptions are provided in the Supplemental Methods.
Analysis of circulating BAs
To determine the concentration of BAs in plasma, BAs were measured with a highly selective reversed phase liquid chromatography-mass spectrometry/mass spectrometry analysis method in negative multiple reaction monitoring detection mode. The BA data were quantified with corresponding mass spectrometry software (AB Sciex, Concord, ON, Canada; Analyst Xcalibur, Thermo Fisher Scientific Life Sciences; Waters Masslynx, Eschborn, Germany) and finally exported into MetIDQ software (BioCrates Life Sciences, Innsbruck, Austria) for comprehensive statistical analysis. Further information is provided in the Supplemental Methods. The BA panel comprised cholic acid, chenodeoxycholic acid (CDCA), deoxycholic acid (DCA), lithocholic acid (LCA), ursodeoxycholic acid (UDCA), hyodeoxycholic acid (HDCA), a-, b-, and v-muricholic acid and their glycine (G) and taurine (T) conjugates, and the sulfated BAs glycolithocholic acid sulfate (GLCAS) and taurolithocholic acid sulfate. Hyodeoxycholic acid and muricholic acids were excluded from the calculations owing to undetectable plasma concentrations. For the calculations, BAs were further grouped as follows: (1) total BAs were all BAs, including conjugated and sulfated forms; (2) primary BAs included cholic acid, CDCA, and conjugates; (3) secondary BAs included DCA, LCA, and UDCA and their conjugates and sulfated forms; and (4) conjugated BAs included all glycine-and taurine-conjugated BAs.
Statistical analysis
Results are expressed as the mean 6 standard error of the mean. Normal distribution was analyzed using the Kolmogorov-Smirnov test. Where necessary, the arithmetic mean and its confidence intervals were calculated on a logarithmic scale for the statistical analyses. Longitudinal changes of mRNA expression, immunometabolic parameters, and BAs were tested using the paired t test and repeated measures analysis of variance for parametric data, whereas nonparametric data were analyzed using Wilcoxon-signed rank test and Freidman's test with post hoc Bonferroni correction. To examine the effect of BAs, FGF19, or GLP-1 on the immunometabolic profile, data were analyzed using a linear mixed model in which the immunometabolic parameters were explained using the time from surgery and BAs, GLP-1, or FGF19 as fixed effects, with the patient identification as random effect. The estimation method applied was the restricted maximum likelihood and Akaike information criterion was used for model selection. A two-tailed P value , 0.05 was considered statistically significant. Statistical analyses were performed using the SPSS statistical software package, version 22.0 (IBM Corp., Armonk, NY). Graphs were built using GraphPad Prism, version 5 (GraphPad Software, La Jolla, CA).
Results
Clinical characteristics and changes in immunometabolic parameters
LAGB resulted in a marked reduction of BMI at 6 and 12 months after surgery (BMI before LAGB, 43.5 6 0.9 kg/m 2 ; BMI after LAGB, 34.9 6 1.1 and 35.8 6
1.6 kg/m 2 , respectively; P , 0.001). This was also reflected by a relevant decrease in circulating leptin (before LAGB, 48.9 6 4.8 ng/mL; 12 months postoperatively, 25.6 6 4.0 ng/mL; P , 0.01). As expected, insulin resistance improved significantly, as displayed by a reduction in the insulin levels (before LAGB, 24.1 6 3.8 mU/L; at 6 months after LAGB, 14.6 6 2.0 mU/L; at 12 months after LAGB, 14.5 6 2.0 mU/L; P , 0.01) and HOMA index (before LAGB, 5.8 6 0.9; at 6 months after LAGB, 3.7 6 0.5; at 12 months after LAGB, 3.2 6 0.5; P , 0.05) at 6 and 12 months after LAGB. Total, highdensity lipoprotein (HDL), and low-density lipoprotein (LDL) cholesterol levels transiently decreased at 3 months postoperatively (total cholesterol, 206.5 6 6.4 to 164.9 6 6.3 mg/dL; HDL, 48.6 6 2.5 to 29.8 6 2.3 mg/dL, P , 0.001; LDL, 130.0 6 5.7 to 106.3 6 5.0 mg/dL, P , 0.05) and 6 months postoperatively (total cholesterol, 176.6 6 5.5 mg/dL, P , 0.01; HDL, 40.6 6 2.4 mg/dL, P , 0.05) but then gradually increased until 12 months after LAGB.
Analysis of liver enzymes revealed a substantial decline of g-glutamyltransferase (gGT) and alkaline phosphatase (AP), surrogate parameters of liver steatosis, 12 months after surgery (gGT, 34.8 6 4.8 to 22.1 6 1.8 U/L; AP, 71.2 6 4.5 to 60.7 6 2.8 U/L, P , 0.05). This is well in line with previous results of liver specimens from 18 patients in the present study cohort, proving a statistically significant reduction in the degree of liver steatosis (5). Although high-sensitive C-reactive protein (CRP) as marker of low-grade inflammation in obesity had decreased significantly 12 months after the intervention (0.8 6 0.1 to 0.4 6 0.07 mg/dL, P , 0.01), the white blood cell count remained unchanged (6.8 6 0.3 to 6.3 6 0.3 g/L). The patient characteristics are presented in Table 1 .
Effect of LAGB on BA profile and BA-induced hormones GLP-1 and FGF19
At 3 months after LAGB, total BA levels had increased significantly (2.5 6 0.4 to 4.4 6 0.7 mM, P , 0.01), subsequently returning to almost baseline levels at 6 and 12 months after surgery (2.9 6 0.5 and 3.5 6 0.7 mM, respectively). This statistically significant, although transient, effect was primarily attributed to an elevation of conjugated and secondary BAs, which also temporarily increased at 3 months after LAGB (conjugated BAs, 1.6 6 0.3 to 3.5 6 0.6 mM; secondary BAs, 1.14 6 0.18 to 2.4 6 0.4 mM; P , 0.01). The primary BA levels, in contrast, did not change significantly (1.3 6 0.3 to 2.0 6 0.3 mM). Regarding specific BAs, GCDCA, TCDCA, DCA, and TDCA had also transiently increased at 3 months after LAGB (GCDCA, 0.54 6 0.10 to 1.06 0.20 mM; TCDCA, 0.08 6 0.02 to 0.23 6 0.07 mM; DCA, 0.27 6 0.04 to 0.47 6 0.08 mM; TDCA, 0.06 6 0.03 to 0.21 6 0.12 mM; P , 0.05). Most interestingly, only a single BA, namely GLCAS, remained significantly elevated during the whole follow-up period (before LAGB, 0.30 6 0.08 mM, at 3 months after, 0.64 6 0.12 mM, at 6 months after, 0.50 6 0.09 mM, and at 12 months after, 0.49 6 0.08 mM). GLCAS also represented the second most common BA within the whole BA pool, accounting for~17% of total BAs 6 months after surgery. The transient elevation of total BAs was paralleled by a substantial increase of fasting GLP-1 at 3 months after LAGB (23.0 6 4.6 to 38.6 6 .9 pmol/L, P , 0.01). In contrast, FGF19 remained elevated throughout the study course (FGF19 before LAGB, 61.5 6 9.8 pg/dL, at 3 months after, 137.0 6 26.0, at 6 months after, 102.1 6 15.0, and at 12 months after, 123.7 6 26.4). All data are presented in Table 2 and Fig. 1 .
Correlations between BAs and immunometabolic parameters, GLP-1 and FGF19
Linear mixed model analysis illustrated a statistically significant association between insulin and the HOMA index with total (P , 0.05) and conjugated (P , 0.05) BAs (Table 3) . No association between HOMA insulin resistance and fasting GLP-1 or FGF19 levels was detected (Table 3) . Glucose levels did not correlate with BAs, FGF19, or fasting GLP-1 levels (Supplemental Table 1). Analysis of the longitudinal changes of CRP revealed a positive association with primary (P , 0.05) and conjugated (P , 0.05) BAs (Table 3 ).
Fasting GLP-1 levels were positively associated with total (P , 0.001), secondary (P , 0.01) and conjugated (P , 0.001) BAs, whereas FGF19 was significantly associated with total (P = 0.001), primary (P , 0.01), secondary (P , 0.01), unconjugated (P , 0.05), and conjugated (P , 0.05) BAs (Table 4) .
Hepatic FXR expression and results of microarray analysis
To detect differences in the expression of hepatic FXR before vs 6 months after surgery, we performed quantitative real-time PCR for analysis of mRNA levels and immunohistochemistry to visualize FXR expression in liver tissue. Neither at the mRNA nor at the protein level could we detect a relevant change in FXR expression (Fig. 2) . Liver specimens of four patients before and 6 months after LAGB were used in a detailed microarray analysis to detect regulation of targets of the hepatic FXR pathway. Considering a false discovery rate of ,10%, no substantial change could be observed for FXR-regulated target genes such as small heterodimer partner (SHP), ATP binding cassette subfamily B member 11 (ABCB11), or cytochrome P450, family 7, subfamily A, polypeptide 1 (CYP7A1; Supplemental Fig. 1 ; Table 2 ).
Discussion
Despite numerous studies showing alterations of BAs after bariatric procedures (13-16), important aspects of BA biology remain unclear, and most studies to date have failed to present a comprehensive analysis of the complete BA pool as performed in the present study. Our results revealed an improvement in the immunometabolic profile after LAGB that is accompanied by a change in BA, GLP-1 and FGF19 levels. The observed increase in BAs occurs early, within 3 months after surgery.
Corresponding to data found after RYGB (14, 27) , indepth analysis of the whole BA spectrum revealed that elevation of total BAs primarily results from an increase in conjugated and secondary BAs. Because the generation of secondary BAs depends on the microbiota (28), this might reflect changes in microbial composition after e Statistical analysis was performed using repeated-measures analysis of variance.
f P , 0.05 vs before LAGB.
LAGB, although this was not investigated in our study. Nevertheless, the mechanisms underlying microbial alterations after LAGB remain complex, because, on the one hand, BAs affect the microbiota by various mechanisms (29) , and, on the other hand, weight loss and diet constitute important drivers for changes in microbial composition (30) . In our study, food ingestion was reduced after LAGB, but no specific diet was dictated. Therefore, we could not exclude that some of the effects on BAs might have been secondary to food restriction and weight loss. Jahansouz et al. (31) , however, demonstrated that BAs increased after surgically induced, but not dietinduced, weight loss, indicating that mechanisms other than dietary changes are of primary importance. Strikingly, only one specific BA, namely GLCAS, remained elevated during the whole follow-up period. GLCAS represents a major metabolite of the secondary BA, LCA (32), which, in humans, is almost exclusively present in its sulfated form (33) . Therefore, the increase of GLCAS presumably reflects enhanced bacterial transformation of CDCA into LCA, which is then further conjugated and sulfated in the liver. Sulfation is expected to reduce toxicity by enhancing fecal and renal excretion. Consequently, sulfated BAs can be primarily detected in the urine, but levels in serum and bile are normally low (33) . In our study, however, GLCAS and GCDCA represented the most common BAs of the whole BA pool, indicating physiological relevance. Because only few data are available about GLCAS, its affinity to receptors such as FXR and its influence on metabolism are so far unknown and should be the subject of future research to clarify the role of this specific BA.
In addition, fasting GLP-1 levels were transiently increased in our cohort at 3 months postoperatively, Abbreviations: GCA, glycocholic acid; GCDCA, glycochenodeoxycholic acid; GDCA, glycodeoxycholic acid; GLCA, glycolithocholic acid; GUDCA, glycoursodeoxycholic acid; TCA, taurocholic acid; TCDCA, taurochenodeoxycholic acid; TDCA, taurodeoxycholic acid; TLCA, taurolithocholic acid; TUDCA, tauroursodeoxycholic acid. a Statistical analysis was performed using repeated measures analysis of variance.
b P , 0.01 vs before LAGB.
c Statistical analysis was performed using Friedman's test.
d P , 0.05 vs before LAGB.
e P , 0.001 vs before LAGB.
f Calculation performed using a linear mixed model to allow for inclusion of cases with missing values (GLP-1 before LAGB, n = 13).
doi: 10.1210/jc.2017-00235 https://academic.oup.com/jcemcorresponding well with the pattern of total, conjugated, and secondary BAs. This contrasts with the results from former studies, which only detected an elevation of GLP-1 after RYGB but not after LAGB (34) . Study data are conflicting regarding whether only postprandial or also fasting GLP-1 levels increase after bariatric procedures (16, 34, 35) . Owing to its induction after food ingestion, postprandial GLP-1 levels were suggested to be more relevant. As we only measured fasting levels, we could not delineate any effects on postprandial GLP-1 concentrations. Interestingly, we observed a positive association between GLP-1 and total, secondary, and conjugated BAs.
Thus, it might be tempting to anticipate that elevated BA concentrations contribute to the increased fasting GLP-1 concentrations via TGR5. In animal models, overexpression of TGR5 in transgenic and deletion in TGR5 knockout mice strongly affected postprandial GLP-1 concentrations, with, however, negligible effects on baseline GLP-1 levels (22) . Therefore, the effect of TGR5 on fasting GLP-1 levels remains unclear, especially because human data are scarce (36) . GLP-1 itself underlies a complex regulation by nutrients, gastrointestinal transit time, BAs, and degrading factors such as dipeptidyl peptidase 4 (36) . As treatment with liraglutide has been shown to decrease fasting endogenous glucose release (37), a net effect of increased fasting GLP-1 levels might contribute to reduced glucose levels under fasting conditions. Consistent with data after RYGB (27) , FGF19 increased significantly in our study population. However, FGF19, which is induced by BAs via ileal FXR (20) , displayed a different course than GLP-1, remaining continuously elevated during the whole follow-up period. Correlations between FGF19 and BAs were analyzed, proving a statistically significant positive association with total, primary, secondary, unconjugated, and conjugated BAs, indicating that BA elevation leads to a consecutive increase in FGF19. Several other studies have demonstrated a positive correlation between BAs and FGF19, confirming our results (16) .
Regarding the metabolic profile, we observed a decline in HDL and LDL cholesterol at 3 months after LAGB, which can be explained by protein malnutrition after surgery, leading to reduced HDL and LDL synthesis.
To investigate whether metabolic improvements and reduction in low-grade inflammation are correlated with changes in BAs, a linear mixed model was calculated. Positive associations were shown between insulin and HOMA index with total and conjugated BAs. Moreover, we detected a positive correlation between CRP and primary and conjugated BAs. These findings were unexpected, because BAs have been suggested to reduce insulin resistance and inflammation via FXR (38) . Previous studies did not show any correlations between BAs and immunometabolic parameters after bariatric procedures, despite the well-accepted effects of BAs on metabolism (16) . Possible explanations include varying observation periods and cohort sizes as well as differences in patient characteristics, especially regarding the diabetes rate at baseline. Therefore, further studies are needed to clarify the correlations between BAs and metabolic parameters after bariatric surgery.
Hepatic protein and glycogen synthesis are upregulated via FGF19, and GLP-1 lowers blood glucose levels by enhancing glucose-dependent release of insulin from pancreatic b-cells (20, 39) . Considering the role of FGF19 and GLP-1 in the regulation of metabolic processes, they might also indirectly mediate the effects of BAs. Nevertheless, in line with current data (16, 27) , neither GLP-1 nor FGF19 was significantly associated with metabolic or inflammatory parameters.
Ryan et al. (11) highlighted the importance of FXR signaling in vertical sleeve gastrectomy-induced weight loss, showing that conventional FXR knockout mice compared with wild-type mice exhibited neither sustained weight loss nor improvement in glucose tolerance. More recent studies using tissue-specific knockout mice have demonstrated that FXR-mediated beneficial effects are mainly driven by ileal, but not hepatic, FXR (40) . Such a concept is supported by our data, which showed no effect on hepatic FXR expression and downstream pathways after LAGB. However, to date, the study results have been ambiguous regarding whether inhibition or activation of ileal FXR by BAs might improve metabolic dysfunction (38, 41) .
Despite a relatively small sample size, we believe our study contributes to the understanding of the role of BAs in the context of weight loss induced by bariatric surgery. In the present study, we have provided a comprehensive analysis of metabolic, inflammatory, and gene expression profiles in conjunction with an in-depth analysis of the complete human BA pool.
In conclusion, our study has demonstrated that BAs and the BA-induced hormones FGF19 and GLP-1 are not only altered after RYGB, but also after LAGB, and might thus be relevant for the metabolic and inflammatory improvements observed after gastric banding despite the unaltered anatomy. Moreover, our results fit with recent concepts implying an important effect of intestinal FXR on metabolism. Thus, our data support an important role of BAs in the regulation of metabolic diseases and adiposity for which new treatment options are desperately awaited.
